JAK2 V617F positive essential thrombocythemia developing in a patient with CD5⁻ chronic lymphocytic leukemia.
- Author:
Ju WEI
1
;
Chun WANG
;
You-Wen QIN
;
Jun ZHU
;
Yang-Rong GAO
;
Qi CAI
;
Shi-Ke YAN
Author Information
1. Department of Hematology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China. weiju@medmail.com.cn
- Publication Type:Case Reports
- MeSH:
Aged, 80 and over;
CD5 Antigens;
metabolism;
Humans;
In Situ Hybridization;
Janus Kinase 2;
genetics;
Leukemia, Lymphocytic, Chronic, B-Cell;
genetics;
metabolism;
Male;
Mutation;
Thrombocythemia, Essential;
genetics;
metabolism
- From:
Chinese Medical Journal
2012;125(11):2076-2079
- CountryChina
- Language:English
-
Abstract:
Coexistence of chronic lymphocytic leukemia (CLL) and essential thrombocythemia (ET) in a patient is extremely rare, with only 10 cases reported thus far in literature. This paper describes a 94-year-old male having atypical B-CLL with CD5⁻ (CD5⁻) phenotype and ET. In this patient, we performed interphase fluorescence in situ hybridization (FISH) analysis which revealed 13q14.3 deletion in 31% of B-lymphocyte nuclei and RB1 deletion in 27% of B-lymphocyte nuclei, but not in neutrophils and T-lymphocytes. Furthermore, we identified JAK2 V617F mutation in the peripheral blood nucleated cells and neutrophils, but not in the B- and T-lymphocyte populations. Therefore, it was concluded that the occurrence of CD5− B-CLL and ET in this patient was pathogenically independent.
